GLP-1 & Incretin Research Peptides: An Overview for Laboratories
A research-context primer on incretin-pathway peptides (Retatrutide, Tirzepatide, Semaglutide) — mechanisms and study areas.
Published October 30, 2026 · PepNova technical team
This article is a research-context primer only. It is not medical advice, and none of the peptides discussed are supplied by PepNova for human use. All are research / animal-use materials.
What incretin pathways are
Incretin hormones help regulate glucose and energy balance. Researchers study peptide agonists of these pathways (such as GLP-1, GIP and glucagon receptors) to understand metabolic mechanisms in preclinical and in-vitro models.
The peptides researchers study
- Semaglutide — a GLP-1 receptor agonist studied in metabolic research.
- Tirzepatide — a dual GIP/GLP-1 receptor agonist of research interest.
- Retatrutide — a triple agonist (GLP-1/GIP/glucagon) explored in metabolic models.
Common research questions
- Receptor binding and selectivity
- Signal transduction in cell models
- Energy-balance and metabolic pathways
- Comparative studies across incretin peptides
Sourcing considerations
For any of these, prioritize verified purity (HPLC), batch-specific COA, and a supplier that is transparent about origin and documentation. Consistency across lots matters more than price for reproducible work.
Compliance
PepNova supplies these sequences as high-purity research / animal-use peptides with full COA and HPLC. They are not approved for human therapeutic use in any market.
Request a Quote
Tell us your target product, quantity and market — we’ll return a tailored quote and a COA sample.
Request a Quote